TransCode Therapeutics (RNAZ) has released an update.
TransCode Therapeutics, Inc. has received a notification from the Nasdaq Office of General Counsel confirming that the company is back in compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. As part of this compliance, the company will be monitored by a Nasdaq panel for one year until January 26, 2025. The company has publicly announced this development through a press release.
For further insights into RNAZ stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
